<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03202550</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00117627</org_study_id>
    <nct_id>NCT03202550</nct_id>
  </id_info>
  <brief_title>Oral Sedation During Cervical Dilator Placement</brief_title>
  <acronym>OSDI</acronym>
  <official_title>Oral Sedation During Cervical Dilator Placement: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society of Family Planning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a randomized, double-blind, placebo-controlled trial involving 2 arms. It will
      be comparing the effects of placebo compared to 1 mg oral lorazepam/5 mg oral oxycodone on
      pain scores during cervical dilator placement prior to dilation and evacuation (D&amp;E).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Potential participants will be first introduced to the study via routine intake call.
      Participants will be identified at the participant's office visits to the Johns Hopkins'
      Women's Center for Family Planning. If a patient desires D&amp;E for a second trimester
      pregnancy, the patient will first receive standard counseling. Only after providing written
      informed consent for the procedure will the patients be screened for eligibility in the
      study. If the patient is eligible the participant will be asked by a member of the research
      team if the patient is interested in participating. If the patient is, the study will be
      explained to the participant and written consent will be obtained after participant is given
      the opportunity to have all questions answered.

      The study is randomized, double-blind, placebo-controlled trial involving 2 arms.
      Participants will first complete a survey to collect demographic data.

      Participants in both arms will receive the institution's current standard analgesia for
      cervical dilator placement. In addition to this standard regimen, participants will be
      randomized to receive either: (1) a dose of two oral placebo pills, or (2) 1mg of oral
      lorazepam with 5 mg of oral oxycodone prior to cervical dilator placement.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 28, 2017</start_date>
  <completion_date type="Actual">May 28, 2019</completion_date>
  <primary_completion_date type="Actual">May 28, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The participant, provider, and nursing staff will be blinded to the intervention. The pharmacy will prepare the treatment drugs and placebos.. Randomization will be stratified by gestational age (&gt;= 20 weeks or &lt;20 weeks) and the randomization allocation sequence will be computer-generated with a random number generator by a statistician. The pharmacist will be aware of the randomization sequence and will dispense the drugs as appropriate, while keeping track of which arms participants were randomized to.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cervical Dilator Placement Pain as Assessed by VAS on a Tablet Device</measure>
    <time_frame>Immediately after the last dilator is placed, up to 1 minute</time_frame>
    <description>Compare pain scores on a 100 mm visual analog scale (VAS) (anchors 0=no pain; 100=worst pain ever)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Desired Number of Dilators Inserted</measure>
    <time_frame>After speculum removed, up to 30 minutes</time_frame>
    <description>Assess whether desired number of dilators was not able to be successfully inserted, comparing 2 arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Pain Score Before Drugs Were Administered</measure>
    <time_frame>pain score given prior to administration of study drugs, up to 1 minute</time_frame>
    <description>Compare pain scores on a 100 mm visual analog scale (VAS) (anchors 0=no pain; 100=worst pain ever)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Score Before Speculum Placement</measure>
    <time_frame>pain score given before specula placed, up to 1 minute</time_frame>
    <description>Compare pain scores on a 100 mm visual analog scale (VAS) (anchors 0=no pain; 100=worst pain ever)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Score After Speculum Placement</measure>
    <time_frame>pain score given at time of speculum placement, up to 1 minute</time_frame>
    <description>Compare pain scores on a 100 mm visual analog scale (VAS) (anchors 0=no pain; 100=worst pain ever)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Score at Tenaculum Placement</measure>
    <time_frame>Immediately scored at time of tenacula placement, up to 1 minute</time_frame>
    <description>Compare pain scores on a 100 mm visual analog scale (VAS) (anchors 0=no pain; 100=worst pain ever)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Score During Paracervical Block</measure>
    <time_frame>pain score given at time of paracervical block administration, up to 1 minute</time_frame>
    <description>Compare pain scores on a 100 mm visual analog scale (VAS) (anchors 0=no pain; 100=worst pain ever)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Score After First Dilator Placement</measure>
    <time_frame>pain score given immediately after first dilator placed, up to 1 minute</time_frame>
    <description>Compare pain scores on a 100 mm visual analog scale (VAS) (anchors 0=no pain; 100=worst pain ever)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Score 15 Minutes After Last Dilator Placed</measure>
    <time_frame>Assessed up to 45 minutes after last dilator placed</time_frame>
    <description>Compare pain scores on a 100 mm visual analog scale (VAS) (anchors 0=no pain; 100=worst pain ever). This was to be assessed at 15 minutes after last dilator is placed. Some participants had this assessment done up to 45 minutes after last dilator was placed because it could not be done at 15 minutes (some were being attended to by a nurse at the 15 minutes mark).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Oral Sedation and Cervical Dilator Pain</condition>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two oral placebo pills (microcrystalline cellulose capsules)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Drug Arm: Lorazepam and Oxycodone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 mg of oral lorazepam and 5 mg of oral oxycodone (also encased in microcrystalline cellulose capsules)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone and Lorazepam (Active Comparator)</intervention_name>
    <description>Oxycodone and Lorazepam</description>
    <arm_group_label>Active Drug Arm: Lorazepam and Oxycodone</arm_group_label>
    <other_name>Oral Oxycodone</other_name>
    <other_name>Oral Lorazepam</other_name>
    <other_name>Ativan</other_name>
    <other_name>OxyIR</other_name>
    <other_name>Roxicodone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>Placebo oral pills</description>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged 18-50 years

          -  English speaking

          -  With an intrauterine pregnancy (either viable or non-viable) between the gestational
             ages of 17w0d and 23w6d

          -  Have a support person present with participant

          -  Have a cell phone capable of text messaging (optional)

        Exclusion Criteria:

          -  Non-English-speaking

          -  Taking a daily benzodiazepine or opiate

          -  Have a known allergy or contraindication to NSAIDs, opiates, or benzodiazepines
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carolyn Sufrin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jessica K Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins' Women's Center for Family Planning</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Mercier RJ, Liberty A. Intrauterine lidocaine for pain control during laminaria insertion: a randomized controlled trial. Contraception. 2014 Dec;90(6):594-600. doi: 10.1016/j.contraception.2014.07.008. Epub 2014 Jul 23.</citation>
    <PMID>25139724</PMID>
  </reference>
  <reference>
    <citation>Soon, R. T., M.; Salcedo. J.; Kaneshiro, B., Paracervical block to decrease pain with second-trimester laminaria insertion: a randomized controlled trial. Contraception 2016, 94 (4), 389.</citation>
  </reference>
  <reference>
    <citation>Wong CY, Ng EH, Ngai SW, Ho PC. A randomized, double blind, placebo-controlled study to investigate the use of conscious sedation in conjunction with paracervical block for reducing pain in termination of first trimester pregnancy by suction evacuation. Hum Reprod. 2002 May;17(5):1222-5.</citation>
    <PMID>11980742</PMID>
  </reference>
  <reference>
    <citation>Wiebe E, Podhradsky L, Dijak V. The effect of lorazepam on pain and anxiety in abortion. Contraception. 2003 Mar;67(3):219-21.</citation>
    <PMID>12618257</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 27, 2017</study_first_submitted>
  <study_first_submitted_qc>June 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2017</study_first_posted>
  <results_first_submitted>February 20, 2020</results_first_submitted>
  <results_first_submitted_qc>February 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 6, 2020</results_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oral Sedation</keyword>
  <keyword>Lorazepam</keyword>
  <keyword>Oxycodone</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Lorazepam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The study plans to share placebo data (without PHI) with colleagues at University of California Davis at the end of the study. A Memorandum of Understanding will be created prior to sharing (MOU) and data will be shared across a secure server.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 17, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT03202550/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Three participants who were enrolled but did not receive the intervention had either chosen not to proceed further with the study or were not able to swallow the study drugs.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo Arm</title>
          <description>Two oral placebo pills (microcrystalline cellulose capsules)
Placebo Comparator: Placebo oral pills</description>
        </group>
        <group group_id="P2">
          <title>Active Drug Arm: Lorazepam and Oxycodone</title>
          <description>1 mg of oral lorazepam and 5 mg of oral oxycodone (also encased in microcrystalline cellulose capsules)
Oxycodone and Lorazepam (Active Comparator): Oxycodone and Lorazepam</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Arm</title>
          <description>Two oral placebo pills (microcrystalline cellulose capsules)
Placebo Comparator: Placebo oral pills</description>
        </group>
        <group group_id="B2">
          <title>Active Drug Arm: Lorazepam and Oxycodone</title>
          <description>1 mg of oral lorazepam and 5 mg of oral oxycodone (also encased in microcrystalline cellulose capsules)
Oxycodone and Lorazepam (Active Comparator): Oxycodone and Lorazepam</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cervical Dilator Placement Pain as Assessed by VAS on a Tablet Device</title>
        <description>Compare pain scores on a 100 mm visual analog scale (VAS) (anchors 0=no pain; 100=worst pain ever)</description>
        <time_frame>Immediately after the last dilator is placed, up to 1 minute</time_frame>
        <population>One participant in the active drug arm was determined to not need to have cervical dilators placed, so this participant was not included in the total number of active drug arm participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Arm</title>
            <description>Two oral placebo pills (microcrystalline cellulose capsules)
Placebo Comparator: Placebo oral pills</description>
          </group>
          <group group_id="O2">
            <title>Active Drug Arm: Lorazepam and Oxycodone</title>
            <description>1 mg of oral lorazepam and 5 mg of oral oxycodone (also encased in microcrystalline cellulose capsules)
Oxycodone and Lorazepam (Active Comparator): Oxycodone and Lorazepam</description>
          </group>
        </group_list>
        <measure>
          <title>Cervical Dilator Placement Pain as Assessed by VAS on a Tablet Device</title>
          <description>Compare pain scores on a 100 mm visual analog scale (VAS) (anchors 0=no pain; 100=worst pain ever)</description>
          <population>One participant in the active drug arm was determined to not need to have cervical dilators placed, so this participant was not included in the total number of active drug arm participants.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" lower_limit="33" upper_limit="82"/>
                    <measurement group_id="O2" value="44" lower_limit="10" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Desired Number of Dilators Inserted</title>
        <description>Assess whether desired number of dilators was not able to be successfully inserted, comparing 2 arms.</description>
        <time_frame>After speculum removed, up to 30 minutes</time_frame>
        <population>One participant in the active drug arm was determined to not need to have cervical dilators placed, so this participant was not included in the total number of active drug arm participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Arm</title>
            <description>Two oral placebo pills (microcrystalline cellulose capsules)
Placebo Comparator: Placebo oral pills</description>
          </group>
          <group group_id="O2">
            <title>Active Drug Arm: Lorazepam and Oxycodone</title>
            <description>1 mg of oral lorazepam and 5 mg of oral oxycodone (also encased in microcrystalline cellulose capsules)
Oxycodone and Lorazepam (Active Comparator): Oxycodone and Lorazepam</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Desired Number of Dilators Inserted</title>
          <description>Assess whether desired number of dilators was not able to be successfully inserted, comparing 2 arms.</description>
          <population>One participant in the active drug arm was determined to not need to have cervical dilators placed, so this participant was not included in the total number of active drug arm participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Pain Score Before Drugs Were Administered</title>
        <description>Compare pain scores on a 100 mm visual analog scale (VAS) (anchors 0=no pain; 100=worst pain ever)</description>
        <time_frame>pain score given prior to administration of study drugs, up to 1 minute</time_frame>
        <population>One participant in the active drug arm was determined to not need to have cervical dilators placed, so this participant was not included in the total number of active drug arm participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Arm</title>
            <description>Two oral placebo pills (microcrystalline cellulose capsules)
Placebo Comparator: Placebo oral pills</description>
          </group>
          <group group_id="O2">
            <title>Active Drug Arm: Lorazepam and Oxycodone</title>
            <description>1 mg of oral lorazepam and 5 mg of oral oxycodone (also encased in microcrystalline cellulose capsules)
Oxycodone and Lorazepam (Active Comparator): Oxycodone and Lorazepam</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline Pain Score Before Drugs Were Administered</title>
          <description>Compare pain scores on a 100 mm visual analog scale (VAS) (anchors 0=no pain; 100=worst pain ever)</description>
          <population>One participant in the active drug arm was determined to not need to have cervical dilators placed, so this participant was not included in the total number of active drug arm participants.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0" upper_limit="6"/>
                    <measurement group_id="O2" value="2" lower_limit="0" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Score Before Speculum Placement</title>
        <description>Compare pain scores on a 100 mm visual analog scale (VAS) (anchors 0=no pain; 100=worst pain ever)</description>
        <time_frame>pain score given before specula placed, up to 1 minute</time_frame>
        <population>One participant in the active drug arm was determined to not need to have cervical dilators placed, so this participant was not included in the total number of active drug arm participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Arm</title>
            <description>Two oral placebo pills (microcrystalline cellulose capsules)
Placebo Comparator: Placebo oral pills</description>
          </group>
          <group group_id="O2">
            <title>Active Drug Arm: Lorazepam and Oxycodone</title>
            <description>1 mg of oral lorazepam and 5 mg of oral oxycodone (also encased in microcrystalline cellulose capsules)
Oxycodone and Lorazepam (Active Comparator): Oxycodone and Lorazepam</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Score Before Speculum Placement</title>
          <description>Compare pain scores on a 100 mm visual analog scale (VAS) (anchors 0=no pain; 100=worst pain ever)</description>
          <population>One participant in the active drug arm was determined to not need to have cervical dilators placed, so this participant was not included in the total number of active drug arm participants.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="1" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Score After Speculum Placement</title>
        <description>Compare pain scores on a 100 mm visual analog scale (VAS) (anchors 0=no pain; 100=worst pain ever)</description>
        <time_frame>pain score given at time of speculum placement, up to 1 minute</time_frame>
        <population>One participant in the active drug arm was determined to not need to have cervical dilators placed, so this participant was not included in the total number of active drug arm participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Arm</title>
            <description>Two oral placebo pills (microcrystalline cellulose capsules)
Placebo Comparator: Placebo oral pills</description>
          </group>
          <group group_id="O2">
            <title>Active Drug Arm: Lorazepam and Oxycodone</title>
            <description>1 mg of oral lorazepam and 5 mg of oral oxycodone (also encased in microcrystalline cellulose capsules)
Oxycodone and Lorazepam (Active Comparator): Oxycodone and Lorazepam</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Score After Speculum Placement</title>
          <description>Compare pain scores on a 100 mm visual analog scale (VAS) (anchors 0=no pain; 100=worst pain ever)</description>
          <population>One participant in the active drug arm was determined to not need to have cervical dilators placed, so this participant was not included in the total number of active drug arm participants.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="12" upper_limit="43"/>
                    <measurement group_id="O2" value="11" lower_limit="3" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Score at Tenaculum Placement</title>
        <description>Compare pain scores on a 100 mm visual analog scale (VAS) (anchors 0=no pain; 100=worst pain ever)</description>
        <time_frame>Immediately scored at time of tenacula placement, up to 1 minute</time_frame>
        <population>One participant in the active drug arm was determined to not need to have cervical dilators placed, so this participant was not included in the total number of active drug arm participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Arm</title>
            <description>Two oral placebo pills (microcrystalline cellulose capsules)
Placebo Comparator: Placebo oral pills</description>
          </group>
          <group group_id="O2">
            <title>Active Drug Arm: Lorazepam and Oxycodone</title>
            <description>1 mg of oral lorazepam and 5 mg of oral oxycodone (also encased in microcrystalline cellulose capsules)
Oxycodone and Lorazepam (Active Comparator): Oxycodone and Lorazepam</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Score at Tenaculum Placement</title>
          <description>Compare pain scores on a 100 mm visual analog scale (VAS) (anchors 0=no pain; 100=worst pain ever)</description>
          <population>One participant in the active drug arm was determined to not need to have cervical dilators placed, so this participant was not included in the total number of active drug arm participants.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31" lower_limit="15" upper_limit="56"/>
                    <measurement group_id="O2" value="50" lower_limit="2" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Score During Paracervical Block</title>
        <description>Compare pain scores on a 100 mm visual analog scale (VAS) (anchors 0=no pain; 100=worst pain ever)</description>
        <time_frame>pain score given at time of paracervical block administration, up to 1 minute</time_frame>
        <population>One participant in the active drug arm was determined to not need to have cervical dilators placed, so this participant was not included in the total number of active drug arm participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Arm</title>
            <description>Two oral placebo pills (microcrystalline cellulose capsules)
Placebo Comparator: Placebo oral pills</description>
          </group>
          <group group_id="O2">
            <title>Active Drug Arm: Lorazepam and Oxycodone</title>
            <description>1 mg of oral lorazepam and 5 mg of oral oxycodone (also encased in microcrystalline cellulose capsules)
Oxycodone and Lorazepam (Active Comparator): Oxycodone and Lorazepam</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Score During Paracervical Block</title>
          <description>Compare pain scores on a 100 mm visual analog scale (VAS) (anchors 0=no pain; 100=worst pain ever)</description>
          <population>One participant in the active drug arm was determined to not need to have cervical dilators placed, so this participant was not included in the total number of active drug arm participants.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57" lower_limit="16" upper_limit="69"/>
                    <measurement group_id="O2" value="51" lower_limit="6" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Score After First Dilator Placement</title>
        <description>Compare pain scores on a 100 mm visual analog scale (VAS) (anchors 0=no pain; 100=worst pain ever)</description>
        <time_frame>pain score given immediately after first dilator placed, up to 1 minute</time_frame>
        <population>One participant in the active drug arm was determined to not need to have cervical dilators placed, so this participant was not included in the total number of active drug arm participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Arm</title>
            <description>Two oral placebo pills (microcrystalline cellulose capsules)
Placebo Comparator: Placebo oral pills</description>
          </group>
          <group group_id="O2">
            <title>Active Drug Arm: Lorazepam and Oxycodone</title>
            <description>1 mg of oral lorazepam and 5 mg of oral oxycodone (also encased in microcrystalline cellulose capsules)
Oxycodone and Lorazepam (Active Comparator): Oxycodone and Lorazepam</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Score After First Dilator Placement</title>
          <description>Compare pain scores on a 100 mm visual analog scale (VAS) (anchors 0=no pain; 100=worst pain ever)</description>
          <population>One participant in the active drug arm was determined to not need to have cervical dilators placed, so this participant was not included in the total number of active drug arm participants.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="16" upper_limit="56"/>
                    <measurement group_id="O2" value="9" lower_limit="2" upper_limit="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Score 15 Minutes After Last Dilator Placed</title>
        <description>Compare pain scores on a 100 mm visual analog scale (VAS) (anchors 0=no pain; 100=worst pain ever). This was to be assessed at 15 minutes after last dilator is placed. Some participants had this assessment done up to 45 minutes after last dilator was placed because it could not be done at 15 minutes (some were being attended to by a nurse at the 15 minutes mark).</description>
        <time_frame>Assessed up to 45 minutes after last dilator placed</time_frame>
        <population>One participant in the active drug arm was determined to not need to have cervical dilators placed, so this participant was not included in the total number of active drug arm participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Arm</title>
            <description>Two oral placebo pills (microcrystalline cellulose capsules)
Placebo Comparator: Placebo oral pills</description>
          </group>
          <group group_id="O2">
            <title>Active Drug Arm: Lorazepam and Oxycodone</title>
            <description>1 mg of oral lorazepam and 5 mg of oral oxycodone (also encased in microcrystalline cellulose capsules)
Oxycodone and Lorazepam (Active Comparator): Oxycodone and Lorazepam</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Score 15 Minutes After Last Dilator Placed</title>
          <description>Compare pain scores on a 100 mm visual analog scale (VAS) (anchors 0=no pain; 100=worst pain ever). This was to be assessed at 15 minutes after last dilator is placed. Some participants had this assessment done up to 45 minutes after last dilator was placed because it could not be done at 15 minutes (some were being attended to by a nurse at the 15 minutes mark).</description>
          <population>One participant in the active drug arm was determined to not need to have cervical dilators placed, so this participant was not included in the total number of active drug arm participants.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" lower_limit="14" upper_limit="44"/>
                    <measurement group_id="O2" value="13" lower_limit="0" upper_limit="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected from subjects for the 1 day that they were enrolled and active in the study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo Arm</title>
          <description>Two oral placebo pills (microcrystalline cellulose capsules)
Placebo Comparator: Placebo oral pills</description>
        </group>
        <group group_id="E2">
          <title>Active Drug Arm: Lorazepam and Oxycodone</title>
          <description>1 mg of oral lorazepam and 5 mg of oral oxycodone (also encased in microcrystalline cellulose capsules)
Oxycodone and Lorazepam (Active Comparator): Oxycodone and Lorazepam</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical laceration</sub_title>
                <description>Laceration occurred when tenaculum was placed on cervix</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Katrina Thaler</name_or_title>
      <organization>Johns Hopkins University</organization>
      <phone>410-550-8506</phone>
      <email>kstouff3@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

